Result of AGM

Arecor Therapeutics PLC

28 June 2024

 

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

RESULT OF AGM

Change of Name of Nominated Adviser and Joint Broker

Cambridge, UK, 28 June 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that at its Annual General Meeting, held today at 12.00 pm, all resolutions were duly passed.

Change of Name of Nominated Adviser and Broker

The Company also announces that its Nominated Adviser and Joint Broker has changed its name to Panmure Liberum Limited following completion of its own corporate merger.

-ENDS-

For more information, please contact:

Arecor Therapeutics plc	www.arecor.com
Dr Sarah Howell, Chief Executive Officer	Tel: [phone] Email: [e-mail]
Susan Lowther, Chief Financial Officer	Tel: [phone] Email: [e-mail]
Mo Noonan, Communications	Tel: [phone] Email: [e-mail]
Panmure Liberum Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking)	Tel: [phone]
WG Partners LLP (Financial Advisor)       Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang	Tel: [phone]
Consilium Strategic Communications Chris Gardner, David Daley, Lindsey Neville	Tel: [phone] Email: [e-mail]

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. 

For further details please see our website, www.arecor.com

 

END